Amyris Enters Into First Product Development and Production Agreement With Royal DSM For Food and Nutrition Molecule
July 17 2017 - 8:51AM
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company,
today announces that it has entered into its first product
development and production agreement with Koninklijke DSM N.V.
(Royal DSM) (AEX:DSM.AS), the global science-based company active
in health, nutrition and materials, to develop a food and nutrition
molecule for which DSM is a major market provider.
As part of the previously announced equity investment DSM is
making into Amyris, DSM and Amyris have agreed to focus on a number
of short- to medium-term product development & production
opportunities in vitamins and other nutritional ingredients. This
agreement is the first of what is expected to be several of such
development and production projects.
As part of the agreement, DSM will partner with Amyris and fund
the development of the technology to produce the specific molecule
that Amyris will scale and supply long term to deliver improved
performance while growing its business. DSM will take the molecule
to market utilizing its channel and market access and take
advantage of Amyris’s biotechnology production, which provides a
lower cost of production than currently available.
"We are very excited to partner with DSM on our first product
development and production agreement," said John Melo, Amyris
President & CEO. "This is the first of what are expected to be
several highly disruptive products addressing major markets where,
together, we can leverage Amyris’s technology platform to reduce
cost for products DSM then takes to market in a cost-advantaged
position."
About Amyris Amyris is the integrated renewable
products company that is enabling the world's leading brands to
achieve sustainable growth. Amyris applies its innovative
bioscience solutions to convert plant sugars into hydrocarbon
molecules and produce specialty ingredients and consumer products.
The company is delivering its No Compromise® products across a
number of markets, including specialty and performance chemicals,
flavors and fragrances, cosmetics ingredients, pharmaceuticals, and
nutraceuticals. More information about the company is available at
www.amyris.com.
Forward-Looking Statements This release
contains forward-looking statements regarding Amyris, and any
statements regarding Amyris other than statements of historical
facts could be deemed to be forward-looking statements. These
forward-looking statements include, among other things, statements
regarding future events (such as expected future development and
production projects between Amyris and DSM, Amyris’s anticipated
cost of production for the molecule subject to the current
development and production agreement with DSM, and Amyris’s
expected future performance and business growth) that involve risks
and uncertainties. These statements are based on management's
current expectations and actual results and future events may
differ materially due to risks and uncertainties, including risks
related to manufacturing capacity at Amyris's Brotas facility,
delays or failures in development, production and commercialization
of products, liquidity and ability to fund capital expenditures,
Amyris's reliance on third parties to achieve its goals, and other
risks detailed in the "Risk Factors" section of Amyris's quarterly
report on Form 10-Q filed on May 15, 2017. Amyris disclaims any
obligation to update information contained in these forward-looking
statements whether as a result of new information, future events,
or otherwise.
Amyris, the Amyris logo and No Compromise are registered
trademarks of Amyris, Inc. All other trademarks are trademarks of
their respective owners.
Contact:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
investor@Amyris.com
pr@Amyris.com
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Apr 2023 to Apr 2024